Videos

Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...

Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.

Mark T. Fleming, MD, discusses the outcomes of a practice-wide Diversity, Equity, and Inclusion training program focusing on unconscious bias and microaggression, that was launched at an independent community oncology and hematology practice.

Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.

Ann Nguyen, PharmD, and Winston Wong, PharmD, discuss efforts to integrate clinical pathways into the OptumCare family of medical practices, touching on aspects of this venture such as financial risks, value-based care models, and remaining...

Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.

Mazie Tsang, MD, MS, discusses a study that evaluated referral patterns and health care utilization among patients with hematologic malignancies who were seen in an embedded outpatient palliative care clinic.

Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...

Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.